GlassScriptPhysician profile
Michael W Stumpf
NPI 1023277530
$1,564.88
in general payments reported to CMS, 2019-2025
21 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.78 · 2020: $71.56 · 2021: $128 · 2022: $226 · 2023: $386 · 2024: $363 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $309.38 | 2023-2025 | |
| Lilly USA, LLC | $226.32 | 2020-2023 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $195.08 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $106.29 | 2022-2025 | |
| Abbvie INC. | $101.32 | 2021-2024 | Vraylar |
| Novo Nordisk INC | $97.59 | 2020-2024 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $83.15 | 2021-2024 | Rexulti, Abilify Maintena |
| Gilead Sciences, INC. | $70.01 | 2019-2025 | |
| Exact Sciences Corporation | $55.20 | 2023-2025 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $53.38 | 2019 | |
| Dexcom, INC. | $47.88 | 2024-2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $44.06 | 2024 | |
| Merck Sharp & Dohme LLC | $27.88 | 2022-2025 | Enflonsia, Capvaxive, Gardasil 9 |
| Abbott Laboratories | $27.39 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.73 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.14 | 2021 | |
| Sobi, INC | $18.25 | 2022 | |
| Dynavax Technologies Corporation | $17.20 | 2024 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $15.34 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.86 | 2022 | |
| Cequr Corporation | $8.43 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stumpf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.